Veraxa Biotech AG announced the advancement of its bispecific antibody drug conjugate (bsADC) program VXA-222 into its next phase following a technical milestone in its collaboration with OmniAb, Inc. The program utilizes an "AND-gate" logic to target two different antigens on solid tumors. Veraxa Biotech AG is a biotechnology company focused on designing and developing next-generation antibody-based therapeutics.
